Moderna Seeks European Nod For Updated COVID-19 Vaccine Shot To Tackle New Dominant Strain
Portfolio Pulse from Vandana Singh
Moderna Inc has submitted a regulatory application to the European Medicines Agency for its updated COVID-19 vaccine targeting the XBB.1.5 sublineage of SARS-CoV-2. The application follows guidance from the European Centre for Disease Prevention and Control and the EMA. Moderna has also generated preliminary clinical data showing an immune response against XBB descendent sublineages. The company is prepared to deliver updated vaccines for the fall vaccination season.
July 03, 2023 | 10:26 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna's submission of a regulatory application for its updated COVID-19 vaccine to the EMA could potentially boost its stock as it shows the company's proactive approach in tackling new strains of the virus.
Moderna's proactive approach in updating its COVID-19 vaccine to tackle new strains of the virus and its readiness to deliver these updated vaccines for the fall vaccination season could potentially increase investor confidence in the company, leading to a positive impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100